Wake Forest Universityhealth Scienc Es — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$9,164	8
2021	Research	$20,759	17
2020	Research	$63,709	21
2019	Research	$129,758	34

Breakdown

Who paid Research payments · program years 2019–2022

Janssen Research & Development, LLC $217,190 79 payments
Medical Device Business Services, Inc. $6,200 1 payment

Studies the money was for Research payments · program years 2019–2022

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation $126,485 28 payments
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens $41,052 15 payments
A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects $12,340 6 payments
A Multi Center Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens $9,729 4 payments
Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone DRVd Versus Lenalidomide Bortezomib and Dexamethasone RVd in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplantation $9,164 8 payments
Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone DRVd Versus Lenalidomide Bortezomib and Dexamethasone RVd in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy and Autologo $7,782 8 payments
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects $7,390 5 payments
De-identified patient-level data from periprosthetic fracture patients in which the DePuy Synthes Proximal Femur Hook Plate was utilized as part of the fracture fixation construct $6,200 1 payment
Study to Evaluate Efficacy and Safety of Darunavir Cobicistat Emtricitabine Tenofovir Alafenamide DCFTAF Regimen Versus Boosted Protease Inhibitor bPI Along With Emtricitabine Tenofovir Disoproxil Fumarate FTCTDF Regimen in Virologically Suppressed HIV1 In $2,480 3 payments
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Tre $768 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.